Physician profile
Gary E Glontz
NPI 1669451258
$340.52
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $45.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.63 | 2019 | |
| Amgen INC. | $83.24 | 2019 | |
| Astellas Pharma US INC | $57.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.05 | 2020 | |
| Lilly USA, LLC | $13.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.06 | 2019 | |
| Abbvie INC. | $11.51 | 2020 | |
| Shionogi INC | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Glontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.